Results 11 to 20 of about 284,051 (203)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

Journal of the American Heart Association, 2019
Nandhini Sehar, Seyed Hamed Hosseini Dehkordi, P Barton Duell   +2 more
exaly   +7 more sources

Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events [PDF]

Journal of the American Heart Association
Background The atherogenic characteristics of heterozygous familial hypercholesterolemia (HeFH) increase the risk of premature atherosclerotic cardiovascular disease including not only coronary artery disease but ischemic stroke.
Teruo Noguchi, Yu Kataoka, Takahito Doi   +2 more
exaly   +4 more sources

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but ...
Raal, Frederick J., Kallend, David, Ray, Kausik K., Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J., Curcio, Danielle, Jaros, Mark J., Leiter, Lawrence A., Kastelein, John J.P., ORION-9 Investigators,   +11 more
core   +8 more sources

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia [PDF]

New England Journal of Medicine, 2020
Evolocumab, a fully human monoclonal antibody directed against proprotein convertase subtilisin-kexin type 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels. Its effects in pediatric patients with heterozygous familial hypercholesterolemia are not known.We conducted a 24-week, randomized, double-blind ...
Santos R. D., Ruzza A., Hovingh G. K., Wiegman A., Mach F., Kurtz C. E., Hamer A., Bridges I., Bartuli A., Bergeron J., Szamosi T., Santra S., Stefanutti C., Descamps O. S., Greber-Platzer S., Luirink I., Kastelein J. J. P., Gaudet D., HAUSER-RCT Investigators, Arca M.   +19 more
openaire   +7 more sources

Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study [PDF]

Lipids in Health and Disease, 2022
Background Heterozygous familial hypercholesterolemia (HeFH) due to low-density lipoprotein receptor (LDLR) mutations predisposes patients to highly elevated levels of cholesterol, and patients are at increased risk of adverse cardiovascular events and ...
Kasper Aalbæk Kjærgaard, Sixten Harborg, Henrik Kjærulf Jensen, Signe Borgquist   +3 more
doaj   +2 more sources

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians [PDF]

Frontiers in Pediatrics, 2023
ObjectivePublished reports describing awareness and knowledge of familial hypercholesterolemia (FH) among pediatricians are few and differ considerably across countries.
Ljiljana Bjelakovic, Lazar Stosic, Aleksandra Klisic, Marko Jovic, Sanja Stankovic, Aleksandra Stankovic, Sasa Pantelic, Danijela Zivkovic, Vladimir Vukovic, Vladimir Vukovic, Bojko Bjelakovic   +10 more
doaj   +2 more sources

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and Ezetimibe Combination Therapy [PDF]

Clinical Case Reports
Heterozygous familial hypercholesterolemia (HeFH) strongly predisposes individuals to atherosclerosis, including coronary artery disease, leading to death from cardiovascular diseases in > 60% of untreated cases.
Katsufumi Nishioka, Sonoko Kondo, Kanako Irie, Takeo Kondo, Takashi Iwase, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka   +9 more
doaj   +2 more sources

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside [PDF]

Drug Design, Development and Therapy, 2021
Anandita Agarwala,1 Renato Quispe,2 Anne C Goldberg,3 Erin D Michos2 1Division of Cardiology, Baylor Scott and White Health, Heart Hospital Baylor Plano, Plano, TX, USA; 2Ciccarone Center for the Prevention of Cardiovascular Disease, Division of ...
Agarwala A, Quispe R, Goldberg AC, Michos ED   +3 more
doaj   +2 more sources

Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there a link? [PDF]

International Journal of Cardiology. Hypertension, 2021
Dyslipidemia is known as a strong risk factor for premature atherosclerotic cardiovascular disease and increased morbidity and mortality and can have an adverse effect on left ventricular function due to direct or indirect macrovascular and/or ...
Antonio Vitarelli
doaj   +2 more sources

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia [PDF]

JACC: Basic to Translational Science
Summary: We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to restore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH) and to enhance the macrophage-specific ...
Carla Borràs, MSc, Marina Canyelles, PhD, Josefa Girona, PhD, Daiana Ibarretxe, MD, PhD, David Santos, BS, Giovanna Revilla, PhD, Vicenta Llorente-Cortes, PhD, Noemí Rotllan, PhD, Petri T. Kovanen, MD, PhD, Matti Jauhiainen, PhD, Miriam Lee-Rueckert, PhD, Luis Masana, MD, PhD, Francisco Arrieta, MD, PhD, Javier Martínez-Botas, PhD, Diego Gómez-Coronado, PhD, Josep Ribalta, PhD, Mireia Tondo, PhD, Francisco Blanco-Vaca, MD, PhD, Joan Carles Escolà-Gil, PhD   +18 more
doaj   +2 more sources